|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar
|
|
2
|
Jung KW, Park S, Kong HJ, Won YJ, Lee JY,
Seo HG, et al: Cancer statistics in Korea: incidence, mortality,
survival, and prevalence in 2009. Cancer Res Treat. 44:11–24. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nguyen DX and Massague J: Genetic
determinants of cancer metastasis. Nat Rev Genet. 8:341–352. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM,
Qiu QY, et al: Use of arsenic trioxide
(As2O3) in the treatment of acute
promyelocytic leukemia (APL): II. Clinical efficacy and
pharmacokinetics in relapsed patients. Blood. 89:3354–3360.
1997.PubMed/NCBI
|
|
5
|
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS,
et al: Studies on treatment of acute promyelocytic leukemia with
arsenic trioxide: remission induction, follow-up, and molecular
monitoring in 11 newly diagnosed and 47 relapsed acute
promyelocytic leukemia patients. Blood. 94:3315–3324. 1999.
|
|
6
|
Munshi NC, Tricot G, Desikan R, Badros A,
Zangari M, Toor A, et al: Clinical activity of arsenic trioxide for
the treatment of multiple myeloma. Leukemia. 16:1835–1837. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lin YC, Li DR and Lin W: Relationship
between radiotherapy enhancing effect of arsenic trioxide and the
proliferation and apoptosis of related protein in nasopharyngeal
carcinoma patients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 27:704–707.
2007.(In Chinese).
|
|
8
|
Welch JS, Klco JM, Gao F, Procknow E, Uy
GL, Stockerl-Goldstein KE, et al: Combination decitabine, arsenic
trioxide, and ascorbic acid for the treatment of myelodysplastic
syndrome and acute myeloid leukemia: a phase I study. Am J Hematol.
86:796–800. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Beer TM, Tangen CM, Nichols CR, Margolin
KA, Dreicer R, Stephenson WT, et al: Southwest Oncology Group phase
II study of arsenic trioxide in patients with refractory germ cell
malignancies. Cancer. 106:2624–2629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chang HS, Bae SM, Kim YW, Kwak SY, Min HJ,
Bae IJ, et al: Comparison of diarsenic oxide and tetraarsenic oxide
on anticancer effects: Relation to the apoptosis molecular pathway.
Int J Oncol. 30:1129–1135. 2007.PubMed/NCBI
|
|
11
|
Han MH, Lee WS, Lu JN, Yun JW, Kim G, Jung
JM, et al: Tetraarsenic hexoxide induces Beclin-1-induced
autophagic cell death as well as caspase-dependent apoptosis in
U937 human leukemic cells. Evid Based Complement Alternat Med.
2012:2014142012.PubMed/NCBI
|
|
12
|
Messmer UK, Pereda-Fernandez C,
Manderscheid M and Pfeilschifter J: Dexamethasone inhibits
TNF-α-induced apoptosis and IAP protein downregulation in MCF-7
cells. Br J Pharmacol. 133:467–476. 2001.
|
|
13
|
Aggarwal BB: Nuclear factor-κB: the enemy
within. Cancer Cell. 6:203–208. 2004.
|
|
14
|
Correia M, Cravo M, Marques-Vidal P,
Grimble R, Dias-Pereira A, Faias S, et al: Serum concentrations of
TNF-alpha as a surrogate marker for malnutrition and worse quality
of life in patients with gastric cancer. Clin Nutr. 26:728–735.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tas F, Duranyildiz D, Argon A, Oguz H,
Camlica H, Yasasever V, et al: Serum levels of leptin and
proinflammatory cytokines in advanced-stage non-small cell lung
cancer. Med Oncol. 22:353–358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guttridge DC, Albanese C, Reuther JY,
Pestell RG and Baldwin AS Jr: NF-κB controls cell growth and
differentiation through transcriptional regulation of cyclin D1.
Mol Cell Biol. 19:5785–5799. 1999.
|
|
17
|
Cui ZG, Hong NY, Guan J, Kang HK, Lee DH,
Lee YK, et al: cAMP antagonizes ERK-dependent antiapoptotic action
of insulin. BMB Rep. 44:205–210. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wajant H, Pfizenmaier K and Scheurich P:
Tumor necrosis factor signaling. Cell Death Differ. 10:45–65. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen G and Goeddel DV: TNF-R1 signaling: a
beautiful pathway. Science. 296:1634–1635. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gaur U and Aggarwal BB: Regulation of
proliferation, survival and apoptosis by members of the TNF
superfamily. Biochem Pharmacol. 66:1403–1408. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Demchenko YN and Kuehl WM: A critical role
for the NFκB pathway in multiple myeloma. Oncotarget. 1:59–68.
2010.
|
|
22
|
Kerbauy DM, Lesnikov V, Abbasi N, Seal S,
Scott B and Deeg HJ: NF-κB and FLIP in arsenic trioxide
(ATO)-induced apoptosis in myelodysplastic syndromes (MDSs). Blood.
106:3917–3925. 2005.
|
|
23
|
Han SS, Kim K, Hahm ER, Park CH, Kimler
BF, Lee SJ, et al: Arsenic trioxide represses constitutive
activation of NF-κB and COX-2 expression in human acute myeloid
leukemia, HL-60. J Cell Biochem. 94:695–707. 2005.
|
|
24
|
Jamnitski A, Levels JH, Oever IA and
Nurmohamed MT: High-density lipoprotein profiling changes in
patients with rheumatoid arthritis treated with tumor necrosis
factor inhibitors: a cohort study. J Rheumatol. 40:825–830. 2013.
View Article : Google Scholar
|
|
25
|
Davies B, Waxman J, Wasan H, Abel P,
Williams G, Krausz T, et al: Levels of matrix metalloproteases in
bladder cancer correlate with tumor grade and invasion. Cancer Res.
53:5365–5369. 1993.PubMed/NCBI
|
|
26
|
Bogenrieder T and Herlyn M: Axis of evil:
molecular mechanisms of cancer metastasis. Oncogene. 22:6524–6536.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vihinen P and Kahari VM: Matrix
metalloproteinases in cancer: prognostic markers and therapeutic
targets. Int J Cancer. 99:157–166. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gilmore TD: Introduction to NF-κB:
players, pathways, perspectives. Oncogene. 25:6680–6684. 2006.
|
|
29
|
Chun KS and Surh YJ: Signal transduction
pathways regulating cyclooxygenase-2 expression: potential
molecular targets for chemoprevention. Biochem Pharmacol.
68:1089–1100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmidt EV: The role of c-myc in
regulation of translation initiation. Oncogene. 23:3217–3221.
2004.
|
|
31
|
Chen ZJ, Parent L and Maniatis T:
Site-specific phosphorylation of IκBα by a novel
ubiquitination-dependent protein kinase activity. Cell. 84:853–862.
1996.
|
